SO
SOPHiA GENETICS S.A.
SOPH · NASDAQ
$7.96 +1.40% (+$0.11)
1M +4.33%
Market Cap $667.8M
P/E Ratio -
Div. Yield -
ROE 136.71%
Bulios Fair Price
$10.6
33.2% upside
Current Price
$7.96
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SOPH is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
4 /100
Expensive P/B 8.03x
P/S 7.75x
EV/EBITDA N/A
Growth
76 /100
Growing Book val. growth 38.24%
Rev. growth 17.56%
FCF growth N/A
Profitability
20 /100
Weak Net margin 93.86%
Op. margin 85.01%
FCF margin 52.95%
Quality
5 /100
Poor ROE 136.71%
ROA 40.77%
Asset turnover 0.43x
Debt
54 /100
Moderate Current ratio 2.69x
Int. coverage -11.22x
Debt/Equity 0.74x
Stability
70 /100
Stable Rev. volatility 13.33%
EPS volatility 23.49%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SOPH
Online
Sector
Healthcare
Industry
Medical - Healthcare Information Services
CEO
Ross Muken
Employees
415
Headquarters
Rolle
Upcoming events
03 NOV
Earnings
Upcoming earnings report